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RUNNING TITLE: Fuoroquinolones and risk of tendon rupture 
 
MAIN POINTS 
• Risk of tendon rupture with fluoroquinolones depends upon timing, cumulative dose and concomitant 
exposure to oral corticosteroids.  
• Absolute risk varied by age and concomitant corticosteroid exposure, affecting elderly patients the 
greatest. 
 
 
 
Abstract 
Background and Objectives 
Tendon rupture can result from fluoroquinolone exposure. The objective of this study was to quantify 
relative and absolute risk and determine how risk is affected by timing of exposure.  
Methods 
The UK Health Improvement Network primary care database was used to perform a nested case-control 
study measuring the association between fluoroquinolone exposure and tendon rupture. Adults with 
tendon rupture were matched on age, sex, general practice and calendar time to four controls selected 
from a cohort prescribed systemic fluoroquinolone or co-amoxiclav antibiotics. The relative and absolute 
risk of tendon rupture with fluoroquinolone exposure was calculated. 
Results 
Current fluoroquinolone exposure was associated with an increased risk of any tendon rupture (adjusted 
incidence rate ratio [aIRR] 1.60, 95%CI 1.23-2.07) and Achilles tendon rupture (aIRR 3.15, 95%CI 2.12-
4.67) that persisted for 60 days. Risk increased with cumulative exposure and was greatest when co-
prescribed with oral corticosteroids (aIRR 19.73, 95%CI 7.93-49.11 for Achilles tendon rupture). The 
adjusted rate difference (aRD) with fluoroquinolone exposure was 2.9 and 2.1 per 10000 patients for 
any and Achilles tendon rupture respectively, and was greatest in people aged ≥60 years prescribed 
concomitant oral corticosteroid therapy (aDR 19.6 for any tendon and 6.6 Achilles tendon rupture per 
10000). No association was seen with co-amoxiclav or statin exposure, or with biceps or other tendon 
ruptures. 
Conclusions  
Risk of tendon rupture with fluoroquinolones depends on timing, cumulative dose and concomitant 
exposure to oral corticosteroids. Absolute risk significantly varied by age and concomitant corticosteroid 
exposure, affecting elderly patients the greatest. 
 
 
 
 
 
 
 
 
 
 
Introduction 
Fluoroquinolone antibiotics are widely used to treat a broad range of infections, including those of the 
urinary respiratory and gastrointestinal systems, with variation in the prevalence of prescribing and 
indications for use within different health systems.[1] However, fluoroquinolones cause important side 
effects as listed in their Summary of Product Characteristics (SPC), which include tendon ruptures that 
are listed as occurring very rarely with a frequency of less than 1 per 10000 patients.[2,3] Tendon 
ruptures manifest as complete or partial rupture of the tendon and are an important cause of morbidity, 
affecting both functional ability and quality of life with treatment often involving invasive surgery.[4,5] 
The incidence of tendon rupture in the general population varies according to tendon site, with estimates 
ranging from 4.7 to 55.2 per 100000 person-years for Achilles tendon rupture, and 2.6 to 5.4 per 100000 
person-years for biceps tendon rupture.[6-8] The mechanism for fluroquinolone-induced tendon rupture 
remains uncertain but has been linked to changes in collagen fibrils following alterations in the regulation 
of matric metalloproteinases associated with non-traumatic rupture.[9] Although some risk factors for 
tendon rupture have been identified such as increasing age, male gender, obesity, diabetes, 
corticosteroid therapy and recreational sports, [10-12] a further understanding of risk factors is needed 
to identify at-risk individuals and minimize unintended harm. 
 
In 1995, the U.S. Food and Drug Administration (FDA) updated fluoroquinolone product labelling with a 
warning about the possibility of tendon rupture, followed by a black box warning in 2008.[13,14] In May 
2016, the FDA conducted a review of disabling and potentially irreversible serious side effects of 
fluoroquinolones resulting in a restriction of their use in less severe infections of acute sinusitis, acute 
bronchitis, and uncomplicated urinary tract infections when other treatment options are available.[15] 
The European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) is also 
reviewing the persistence of fluoroquinolones adverse reactions to help determine the need for any 
restriction in indication, and requires further data to characterise the risk of such reactions.[16] Whilst 
the risk of tendon rupture is recognized, there is inconsistency in its reported size with relative risk 
ranging between 1.9 and 5.3-fold increased risk, with limited information on absolute risk.[10,17-22] 
The aim of this study was to quantify the relative and absolute risk of tendon rupture with fluoroquinolone 
exposure, and to investigate factors influencing this risk.  
 
 
 
Methods 
Data source 
The THIN database contains electronic patient records extracted from >500 general practices across the 
UK covering approximately 6% of the UK population. Data is representative of the UK population in terms 
of age, gender, deprivation status, and geographical distribution.[23] Data is linked via an anonymous 
ID number allowing patients to be followed longitudinally over time. THIN contains diagnostic, 
prescription, and lifestyle information. Diagnoses, symptoms, procedures, and other relevant health 
information are coded using the Read Code clinical classification system. The Read code system has been 
the standard approach to recording patient data in UK primary care since 1990, and is a hierarchical 
classification system, linked to the International Classification of Diseases.[24] Data quality control 
measures available in THIN include The Acceptable Mortality Reporting (AMR) date specific to each 
practice and defines the date from which computerised recording of mortality data has reached an 
acceptable standard.[25] 
 
Study Population 
The study population consisted of adults ≥18 years identified in THIN between 01/01/1999 and 
31/12/2015 who were issued at least one prescription of co-amoxiclav or fluoroquinolone antibiotic with 
a systemic route of administration. Co-amoxiclav was chosen so that controls were sampled from a more 
representative population prescribed antibiotics to circumvent problems related to confounding by 
indication and by severity. Cohort entry was defined as the date of the first co-amoxiclav or 
fluoroquinolone prescription for systemic administration after the latest of the following criteria: start of 
the study period (01/01/1999); the practices AMR date; the patient’s 18th birthday; date of registration 
with a general practice + one year. In this regard, all participants were required to have at least one 
year of observation prior to cohort entry. Cohort exit was defined by the earliest of the following criteria: 
occurrence of the outcome; deregistration from the general practice; death; date of last data collection 
from the general practice; end of the study period (31/12/2015). 
 
Study design and outcomes 
A nested case control study was used to efficiently account for time-varying confounders and time-
varying exposure to prescribed medicines.[26] The date of the first event occurring after cohort entry 
was the index date for case subjects. Tendon ruptures were first evaluated as any tendon ruptures and 
were then grouped according to their incidence: Achilles tendon; biceps tendon; and other tendon 
 
 
 
ruptures (consisting of triceps, hand/wrist, hamstrings/quadriceps, foot, shoulder, and non-specifically 
coded tendon ruptures) (see supplementary table S1) 
 
Control selection 
Up to 4 controls were randomly selected and matched to each case on age decile, gender, general 
practice and calendar year of cohort entry using incidence density sampling.[26] The risk-set date for 
controls was the index date for cases. With incidence density sampling, ‘controls’ are a selection of 
person-moments from individuals who have not experienced the event at the index date. In this regard, 
controls may be selected more than once, and people who subsequently become cases may be selected 
as controls at earlier time points. 82 cases of tendon rupture (1.7%) were unmatched to controls 
following the first round of matching criteria, and were subsequently included matched on age decile, 
gender and calendar year of cohort entry only, with sensitivity analyses conducted excluding these risk 
sets from the analysis. 
 
Exposures 
Systemic fluoroquinolone (ciprofloxacin, moxifloxacin, levofloxacin, norfloxacin and ofloxacin) and co-
amoxiclav antibiotic exposure was measured by identifying prescriptions issued within a pre-specified 
risk window prior to the index date. Fluoroquinolone and co-amoxiclav exposure was primarily defined 
as current exposure when one or more prescriptions were issued in a 30 day exposure risk window prior 
to the index date. Exposure risk windows 31-60 days, 61-90 days and 91-180 days prior to the index 
date were then examined for systemic fluoroquinolone exposure to assess past exposure. Cumulative 
fluoroquinolone and co-amoxiclav exposure was measured as the total number of days of systemic 
fluoroquinolone or systemic co-amoxiclav exposure prescribed within each risk window. Cumulative days 
exposure was calculated by dividing the prescription quantity information by the standard administration 
schedule for each type of antibiotic as follows: oral co-amoxiclav three times a days; oral levofloxacin, 
moxifloxacin and norfloxacin once a day; ciprofloxacin and ofloxacin twice a day.[27] Prescriptions for 
oral suspension formulations were similarly calculated taking into account quantity information recorded 
in milliliters. Cumulative exposure was examined as a continuous variable predicting the increased risk 
associated with each additional day of therapy during the risk window and also modelled with a 
categorical variable using the median days of exposure and interquartile range. 
 
 
 
 
 
Confounders 
Analyses were adjusted for exact age, sex and practice-level socioeconomic deprivation (inherent in the 
matching criteria), smoking status, body mass index (BMI), exposure to oral and injectable corticosteroid 
therapy and statin therapy (defined as by prescriptions issued within 90 days of the index date), and 
prior history of tendon rupture. Comorbidity was accounted by adjusting for a history of hypothyroidism, 
hyperparathyroidism and the Charlson comorbidity index, and then by modelling individual conditions in 
the Charlson comorbidity index as a sensitivity analysis. The Charlson comorbidity index is defined using 
the following clinical conditions: myocardial infarction, congestive heart failure, peripheral vascular 
disease, dementia, cerebrovascular disease, chronic lung disease, connective tissue disease, peptic ulcer, 
chronic liver disease, diabetes, hemiplegia, moderate or severe kidney disease, diabetes with 
complications, liver disease, cancer, cancer with metastasis, and AIDS.[28] 
 
Data analysis 
Conditional logistic regression was used to calculate odds ratios for the association between tendon 
rupture and fluoroquinolone exposure and co-amoxiclav exposure. Using an incidence density sampling 
approach, odds ratios calculated in this way are estimators of incidence rate ratios (IRR). Interaction 
between fluoroquinolone exposure and oral corticosteroid exposure was tested on the multiplicative 
scale. This was not done for statins as there was no statistically significant independent association with 
exposure. Adjusted rate differences (per 10000) were calculated for significant associations providing an 
absolute measure of effect.[29] Risk of exposure was presented for any tendon rupture and by type of 
tendon rupture. 
 
Multiple imputation was used to impute missing data on body mass index (9.5% missing) and smoking 
status (2.1% missing). The imputation model included all variables relating to clinical characteristics, 
outcomes, medications, and fluoroquinolone and co-amoxiclav exposure. Multiple imputation used fully 
conditional specification, with linear regression for continuous variables (BMI) and logistic regression for 
categorical variables (smoking status) with five imputations and analysed using Rubin’s rules.[30] 
Sensitivity analyses were conducted varying the exposure risk window duration to 60 and 90 days, 
modelling individual Charlson comorbidities, excluding traumatic tendon ruptures, excluding people with 
prior history of tendon rupture, and undertaking a complete case analysis. Analysis was carried out using 
SAS Enterprise Guidev7.1 and STATAv15. The study was approved by the THIN Scientific Review 
Committee (17THIN087). 
 
 
 
Results 
The cohort contained 1351780 adult patients prescribed ≥1 prescription for fluoroquinolone (34.3%) or 
co-amoxiclav (65.7%) antibiotics (mean age of cohort 52.8 years, 57.0% female). Overall, 4,836 tendon 
rupture events were identified during cohort follow-up (incidence of any tendon rupture 5.9 per 10,000 
person-years (pyrs) and of Achilles tendon rupture 1.9 per 10000 pyrs) that were matched to 18356 
controls (table 1). Cases and controls were well matched on age, sex and duration of follow-up. The 
most common types of tendon rupture were: Achilles tendon (32.4%); biceps tendon (27.5%); shoulder 
tendons (16.6%); hand/wrist tendons (7.4%); hamstring/quadriceps/patellar tendons (7.0%); 
foot/ankle tendons (0.8%) and triceps tendon (0.5%). Unspecified tendon ruptures accounted for 8.3% 
of all cases. The mean duration of cumulative fluroquinolone exposure was 10.6 days (standard 
deviation, SD 8.9 days) and for co-amoxiclav was 8.6 days (SD 7.4 days). 
 
Risk of tendon rupture with fluoroquinolone exposure 
The relative incidence of any tendon rupture was significantly elevated with current systemic 
fluoroquinolone exposure (adjusted IRR [aIRR] 1.61, 95%CI 1.25-2.09). When stratified by type of 
tendon rupture, current fluoroquinolone exposure was associated with a significantly elevated rate of 
Achilles tendon rupture (aIRR 3.14, 95%CI 2.11-4.65) but not biceps tendon rupture (aIRR 1.07, 95%CI 
0.61-1.89) or other tendon ruptures (aIRR 0.82, 95%CI 0.50-1.35) (table 2). In contrast, the relative 
incidence of tendon ruptures was not significantly elevated with current co-amoxiclav exposure (table 
2). 
 
Increasing cumulative days of systemic fluoroquinolone exposure was significantly associated with in 
increased risk of Achilles tendon rupture (IRR 1.06, 95%CI 1.03-1.09). In contrast, no significant 
association was observed with cumulative co-amoxiclav exposure (supplementary table S2). The relative 
incidence of Achilles tendon rupture was significantly increased with systemic fluoroquinolone exposure 
within 1-30 days (aIRR 2.97, 95%CI 1.98-4.43) and 31-60 days (aIRR 2.11, 95%CI 1.30-3.41) of the 
index date but not with systemic fluoroquinolone exposure occurring further in the past (aIRR 0.69, 
95%CI 0.41-1.16 for 61-90 days and aIRR 1.23, 95%CI 0.88-1.71 for 91-180 days prior to the index 
date). 
 
 
 
 
 
 
Relationship with other risk factors 
The adjusted relative incidence of tendon rupture was significantly elevated in people with a history of 
prior tendon rupture, in those with oral corticosteroid therapy, and with increasing BMI (table 3). The 
risk of tendon rupture was not significantly associated with statin therapy or comorbidity score whilst 
smoking was associated with a reduced relative incidence of tendon rupture. A large significant 
interaction was observed with concomitant systemic fluoroquinolone and oral corticosteroid exposure 
(aIRR 6.88, 95%CI 3.94-12.03 and aIRR 19.36, 95%CI 7.78-48.19, for any tendon rupture and Achilles 
tendon rupture respectively, table 4).  
 
Absolute risk 
Adjusted rate differences for any tendon rupture and Achilles tendon rupture are presented overall and 
for age and sex (table 5). Fluoroquinolone exposure caused an estimated 2.9 tendon ruptures and 2.1 
Achilles tendon ruptures per 10000 patients per year and was greatest in patients aged 60 and over. 
Concomitant oral corticosteroid exposure had a large impact on absolute risk with the highest rates of 
tendon rupture associated with concomitant fluoroquinolone and corticosteroid exposure in males and in 
patients aged 60 years and over. 
 
Sensitivity analyses 
The relative incidence was elevated using 60 day and 90 day risk windows but was smaller in size with 
increasing risk-window duration, whilst the results of all other sensitivity analyse were similar to those 
in the main analysis (supplementary table S3). 
 
Discussion 
Fluoroquinolone exposure significantly increased the risk of tendon rupture which appeared to last up to 
60 days following exposure for Achilles tendon rupture. Risk was also estimated to increase by ~6% with 
each additional day exposed to fluoroquinolones within the current risk window and was increased 
markedly with concomitant exposure to oral corticosteroids. In contrast, co-amoxiclav exposure, which 
was chosen as a negative control, was not associated with an increased relative risk of any tendon 
rupture. Absolute risk of tendon rupture from fluoroquinolone exposure was greater than currently 
highlighted by product information and varied markedly according to age and concomitant exposure to 
oral corticosteroids. 
 
 
 
 
Observational studies have previously investigated the risk of tendon rupture with fluoroquinolones with 
results varying in the size and precision of estimates. One case-control study consisting of only 38 cases 
of Achilles tendon rupture, reported a relative risk with current exposure to fluoroquinolone antibiotics 
of 1.9 (95%CI 1.3-2.6), whilst a larger case control study from Italy reported an 30% increased risk of 
any tendon rupture and a larger but less precise risk of Achilles tendon rupture (OR 4.1, 95%CI 1.8-9.6 
for Achilles tendon rupture).[17,19] Meanwhile, a small cohort study from Denmark has reported an 
age-standardized incidence ratio of Achilles tendon rupture of 3.1 (95%CI 1.0-7.3) within 90 days of 
incident fluoroquinolone exposure whilst a further case-control study reported a larger risk of Achilles 
tendon rupture (OR 5.3, 95%CI 1.8-15.2).[18,20] However, these studies did not include an antibiotics-
treated comparator in their design to help assess the presence of residual confounding. 
 
One case-crossover study, whereby the patient acts as their own control, reported a smaller association 
with Achilles tendon rupture (OR 2.0, 95%CI 1.2-3.3) and used a composite of nitrofurantoin, amoxicillin 
and trimethoprim exposure as a negative control with no significant association being observed.[10] This 
comparator group consisted of medications weighted towards the treatment of milder urinary tract 
infections. In contrast, a cohort study from Canada reporting an increased risk of tendon rupture with 
fluoroquinolones did use an active comparator of amoxicillin exposure that was also significantly 
associated with tendon rupture, suggesting the presence of residual confounding can affect the validity 
and size of the relative risk.[21] We used co-amoxiclav as a negative control because in the UK, co-
amoxiclav is a similar broader-spectrum antibiotic reserved for more severe types of infection and may 
be less subject to unmeasured confounding compared to amoxicillin, nitrofurantoin and trimethoprim. 
Similar to fluoroquinolones, co-amoxiclav is also associated with an increased risk of Clostridium difficile 
infection, which has resulted in similar changes to UK antibiotic prescribing guidelines during the study 
period.  
 
Our study extends knowledge by demonstrating that risk appears to be present up to 60 days following 
treatment and increases by ~6% with each days of current exposure. People with prior tendon rupture, 
comorbidity, those with increasing BMI and those prescribed oral corticosteroid exposure were at 
increased risk of tendon rupture, with a significant interaction detected between concomitant 
fluoroquinolone and oral corticosteroid therapy. This interaction has previously been reported but with 
variable precision, ranging from an odds ratio of 9.1 to 43.2.[10,17,20] Information on absolute risk is 
limited. van der Linden et al. report an excess absolute risk of Achilles tendon rupture of 3.2 cases per 
 
 
 
1000 patient years, although the method used to calculate this was not reported.[17] In a related study, 
van der Linden et al. report the incidence of Achilles tendon rupture in people aged 60 and over as a 
population-attributable risk estimating that 2.2% of Achilles tendon rupture in patients age 60 to 79 
years and 6.3% in patients aged 80 years and over are attributable to fluoroquinolone exposure.[18] 
This risk may be dependent on the prevalence of exposure in the population. Although low, we found 
that absolute risk in this population was greater than that listed in the product information for 
fluoroquinolones (which states less than 1 in 10000 patients). Although we estimate a population-
average adjusted rate difference (akin to excess risk) of ~2.9 tendon ruptures per 10000 person years, 
absolute risk was greater is certain subgroups, significantly varying by age, concomitant corticosteroid 
exposure and to a lesser extent, by gender. Lastly, statin therapy has previously been linked to tendon 
disorders using spontaneous reports and pharmacovigilance databases.[31] Our study found no 
significant increased risk with statin use, in keeping with three other recent observational studies.[32-
34] 
 
Our study has strengths and limitations. We matched on general practice so that controls were more 
likely to have similar socio-economic deprivation status and health care physician prescribing behavior 
helping to reduce confounding by indication. Only small numbers of cases were included unmatched on 
general practice, with sensitivity analysis demonstrating this had negligible influence on the observed 
results. Despite adjustment for multiple confounders, risk of residual unmeasured confounding remains 
possible that may include channeling bias, although evaluating the risk of tendon rupture with co-
amoxiclav exposure consistently showed no statistically significant association. Very few traumatic 
tendon ruptures were explicitly recorded and it is not possible to determine what proportion of other 
events may have been associated with trauma, if any. Antibiotic exposures were identified through 
prescriptions issued within general practice. Our study focuses on tendon rupture only and further 
investigation on the risk of tendinitis may be useful for clinical decision making. Similarly, we focus on 
fluoroquinolone as a class and risk associated with individual fluoroquinolone products requires further 
evaluation. 
 
Antibiotic stewardship aimed at reducing fluoroquinolone exposure may prevent unnecessary harm but 
this may not be possible or appropriate for all patients. Despite the relatively large increase in risk 
associated with concomitant exposure to systemic fluoroquinolones and corticosteroids relatively little 
attention is given to this interaction among clinical guideline recommendations. This may have 
 
 
 
implications for special patient groups such as for in the management of asthma, COPD, or bronchiectasis 
exacerbations which may require concomitant use of both antibiotics and oral corticosteroids regimens 
for example and commonly have other risk factors such as comorbidity.[35-37] This study was conducted 
to provide further information to quantify the risk of tendon ruptures associated with fluoroquinolone 
antibiotics to support a review of safety information at the EMA PRAC in order to aid regulatory decision 
making for the use of fluoroquinolones across Europe. In this regard, tendon rupture is only one potential 
adverse effect of fluoroquinolone exposure, with other potential adverse effects associated with 
peripheral neuropathy and aortic aneurysm having been reported.[38, 21, 39-41] 
 
In conclusion, the risk of tendon rupture associated with fluoroquinolone therapy appears to depend on 
timing, dose and concomitant exposure to corticosteroids that affects elderly patients the greatest in 
absolute terms, which patients and healthcare professionals should be informed of. 
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Table 1. Characteristics of matched cases and controls. 
 Cases Controls 
Number of individuals 4836 18356 
Female sex, no. (%) 1876 (38.8) 7164 (39.0) 
Age (years), mean ± SD 61.6 (15.5) 61.3 (15.3) 
Years of follow-up, mean ± SD 5.0 (3.7) 5.0 (3.7) 
Body mass index, mean ± SD 28.1 (5.9) 27.7 (5.7) 
Charlson comorbidity index, mean ± SD 1.32 (1.61) 1.27 (1.64) 
Hypothyroidism, no. (%) 365 (7.6) 1296 (7.1) 
Hyperparathyroidism, no. (%) 17 (0.3) 61 (0.3) 
Current smokers, no. (%) 765 (16.1) 3371 (18.8) 
Oral corticosteroid therapya, no. (%) 522 (10.8) 911 (5.0) 
Injectable corticosteroid therapya, no. (%) 43 (0.9) 32 (0.2) 
Statin therapya, no. (%) 326 (20.7) 1240 (20.6) 
Current fluoroquinolone exposure, no. (%) 111 (2.3) 236 (1.3) 
Current co-amoxiclav exposure, no. (%) 98 (2.0) 314 (1.7) 
Prior history of tendon rupture, no. (%) 133 (2.8) 114 (0.6) 
a = At least one prescription within 90 days of the index date. Current fluoroquinolone exposure=prescription within 30 
days of the index date. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Incidence rate ratios for the association between tendon rupture and current 
systemic fluoroquinolone and co-amoxiclav exposure. 
Tendon rupture Exposed 
cases/total 
Exposed 
controls/total 
Crude IRR Adjusted IRR Adjusted  
p-value 
Any tendon rupture      
 Fluoroquinolones 111/4836 236/18356 1.79 (1.41-2.27) 1.61 (1.25-2.09) <0.001 
 Co-amoxiclav 98/4836 314/18356 1.15 (0.90-1.45) 1.02 (0.79-1.31) 0.900 
Achilles tendon rupture      
 Fluoroquinolones 67/1577 82/6007 3.50 (2.45-5.02) 3.14 (2.11-4.65) <0.001 
 Co-amoxiclav 38/1577 114/6007 1.19 (0.81-1.77) 1.00 (0.64-1.57) 0.989 
Biceps tendon rupture      
 Fluoroquinolones 20/1316 62/4946 1.19 (0.71-2.00) 1.07 (0.61-1.89) 0.804 
 Co-amoxiclav 23/1316 74/4946 1.16 (0.72-1.88) 1.01 (0.61-1.66) 0.978 
Other tendon rupture      
 Fluoroquinolones 24/1943 92/7403 0.94 (0.59-1.50) 0.82 (0.50-1.35) 0.439 
 Co-amoxiclav 37/1943 126/7403 1.09 (0.75-1.60) 1.01 (0.68-1.50) 0.946 
IRR=incidence rate ratio. Model adjusted for exact age, body mass index, Charlson comorbidity score, hypothyroidism, 
hyperparathyroidism, smoking status, oral and injectable corticosteroid therapy, statin therapy and prior history of tendon rupture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Association with any tendon rupture and Achilles tendon rupture and other 
potentially confounding variables and comorbidities. 
 Any tendon rupture Achilles tendon rupture 
Variable Adjusted  
IRR 
Adjusted  
p-value 
Adjusted          
IRR 
Adjusted  
p-value 
Prior tendon rupture 4.60 (3.51-6.04) <0.001 7.48 (4.53-12.35) <0.001 
Oral corticosteroid  2.25 (1.99-2.54) <0.001 3.60 (2.89-4.48) <0.001 
Injectable corticosteroid 5.47 (3.36-8.91) <0.001 1.82 (0.40-8.29) 0.435 
Fluoroquinolone  1.61 (1.25-2.09) <0.001 3.14 (2.11-4.65) <0.001 
Co-amoxicalv 1.02 (0.79-1.31) 0.900 1.00 (0.64-1.57) 0.989 
Body Mass Index 1.01 (1.01-1.02) <0.001 1.01 (1.00-1.03) 0.008 
Statin therapy 1.06 (0.98-1.16) 0.129 0.96 (0.81-1.14) 0.650 
Hypothyroidism 1.03 (0.90-1.17) 0.693 0.91 (0.70-1.18) 0.469 
Hyperthyroidism 0.89 (0.51-1.55) 0.676 1.08 (0.41-2.89) 0.873 
Charlson comorbidity 0.99 (0.97-1.01) 0.279 1.00 (0.96-1.05) 0.975 
  Connective tissue disease 2.03 (1.66-2.49) <0.001 1.02 (0.63-1.65) 0.942 
  COPD 1.07 (0.99-1.17) 0.096 1.24 (1.08-1.44) 0.003 
  Cancer 0.97 (0.88-1.06) 0.473 0.98 (0.81-1.19) 0.854 
  Chronic kidney disease 0.96 (0.86-1.07) 0.452 1.02 (0.82-1.28) 0.865 
  Dementia 0.47 (0.34-0.66) <0.001 0.34 (0.14-0.79) <0.001 
  Diabetes 1.01 (0.91-1.11) 0.854 1.03 (0.85-1.25) 0.758 
  Heart failure 0.85 (0.71-1.01) 0.062 0.87 (0.64-1.25) 0.459 
  Liver disease 0.87 (0.56-1.34) 0.521 1.04 (0.49-2.23) 0.916 
  Myocardial infarction 1.07 (0.92-1.23) 0.404 0.96 (0.71-1.30) 0.796 
  Peptic ulcer disease 1.09 (0.94-1.27) 0.263 1.01 (0.76-1.36) 0.921 
  Peripheral vascular disease 0.90 (0.65-1.25) 0.543 0.85 (0.46-1.57) 0.606 
  Stroke 1.04 (0.90-1.21) 0.579 1.03 (0.75-1.41) 0.878 
Smoking     
 Ex-smoker  1.04 (0.96-1.12) 0.360 0.85 (0.74-0.98) 0.029 
 Current smoker 0.85 (0.78-0.94) 0.001 0.72 (0.61-0.85) <0.001 
IRR = incident rate ratio. Variables included separately in the model without interactions. 
 
 
 
 
 
 
 
Table 4. Incidence rate ratios for the interaction between tendon rupture and current systemic 
fluoroquinolone and oral corticosteroid exposure 
 
 
Exposed 
cases/total 
Exposed 
controls/total 
Adjusted          
IRR 
Adjusted 
p-value 
Any tendon rupture     
 Oral corticosteroid alone 287/4836 443/18356 2.58 (2.19-3.03) <0.001 
 Oral corticosteroid plus 
fluoroquinolone exposure 
36/4836 20/18356 6.88 (3.93-12.03) <0.001 
Achilles tendon rupture     
 Oral corticosteroid alone 148/1557 180/6007 4.59 (3.43-6.14) <0.001 
 Oral corticosteroid plus 
fluoroquinolone exposure 
37/1557 10/6007 19.36 (7.78-48.19) <0.001 
Adjusted for exact age, body mass index, Charlson comorbidity score, hypothyroidism, hyperthyroidism, injectable corticosteroid 
therapy, smoking status, statin therapy and prior history of tendon rupture. IRR=incidence rate ratio. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Adjusted rate differences in tendon rupture with fluoroquinolone exposure and 
concomitant oral corticosteroid exposure (per 10000 patients). 
 Any tendon  Achilles tendon 
 ARD 95%CI ARD 95%CI 
Fluoroquinolone exposure     
 Overall 2.9 2.2-3.7 2.1 1.6-2.7 
 Males 2.3 1.8-3.0 1.6 1.3-2.1 
 Females 3.1 2.4-4.0 2.1 1.6-2.7 
 Age <60 years 1.4 1.0-1.8 1.2 0.9-1.6 
 Age ≥60 years 5.6 4.3-7.2 3.0 2.3-3.9 
Fluoroquinolone plus prednisolone exposure     
 Overall 10.9 8.3-14.0 4.9 3.7-6.2 
 Males 14.6 11.2-18.8 5.5 4.2-7.1 
 Females 7.9 6.0-10.1 3.9 3.0-5.0 
 Age <60 years 6.0 4.6-7.7 2.1 1.6-2.7 
 Age ≥60 years 19.6 15.0-25.2 6.6 5.0-8.4 
       ADR=adjusted rate difference, the additional number of expected events per 10,000 patients per year. 
 
 
 
